Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency.

Ginn SL, Hallwirth CV, Liao SH, Teber ET, Arthur JW, Wu J, Lee HC, Tay SS, Hu M, Reddel RR, McCormack MP, Thrasher AJ, Cavazzana M, Alexander SI, Alexander IE.

Mol Ther Nucleic Acids. 2017 Mar 17;6:1-14. doi: 10.1016/j.omtn.2016.11.011. Epub 2016 Dec 10.

2.

Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman MS, Rowe JM, De Keersmaecker K, Califano A, Ferrando AA.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2006-2011. doi: 10.1073/pnas.1611831114. Epub 2017 Feb 7.

PMID:
28174276
3.

High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.

Chiang MY, Wang Q, Gormley AC, Stein SJ, Xu L, Shestova O, Aster JC, Pear WS.

Blood. 2016 Nov 3;128(18):2229-2240. Epub 2016 Sep 26.

PMID:
27670423
4.

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Cramer SD, Aplan PD, Durum SK.

Blood. 2016 Jul 28;128(4):473-8. doi: 10.1182/blood-2016-03-679209. Epub 2016 Jun 6. Review.

PMID:
27268088
5.

Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL.

Stein SJ, Mack EA, Rome KS, Pajcini KV, Ohtani T, Xu L, Li Y, Meijerink JP, Faryabi RB, Pear WS.

PLoS One. 2016 May 18;11(5):e0155408. doi: 10.1371/journal.pone.0155408. eCollection 2016.

6.

Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders.

Chiang MY, Radojcic V, Maillard I.

Curr Opin Hematol. 2016 Jul;23(4):362-70. doi: 10.1097/MOH.0000000000000254.

PMID:
27135981
7.

Collaborating Pathways that Functionally Amplify NOTCH1 Signals in T-Cell Acute Lymphoblastic Leukemia.

Pinnell NE, Chiang MY.

J Hematol Transfus. 2013;1(1). pii: 1004. Epub 2013 Sep 2. No abstract available.

8.

Targeting Notch to overcome radiation resistance.

Yahyanejad S, Theys J, Vooijs M.

Oncotarget. 2016 Feb 16;7(7):7610-28. doi: 10.18632/oncotarget.6714. Review.

9.

Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.

Yoon SO, Zapata MC, Singh A, Jo WS, Spencer N, Choi YS.

Apoptosis. 2014 Nov;19(11):1616-26. doi: 10.1007/s10495-014-1029-5.

10.

The challenge of targeting notch in hematologic malignancies.

Hernandez Tejada FN, Galvez Silva JR, Zweidler-McKay PA.

Front Pediatr. 2014 Jun 10;2:54. doi: 10.3389/fped.2014.00054. eCollection 2014. Review.

11.

Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.

Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC.

J Clin Invest. 2014 Feb;124(2):644-55. doi: 10.1172/JCI65093. Epub 2014 Jan 9.

12.

c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.

Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, Silverman LB, Sallan SE, Gutierrez A, Look AT, Qi J, Bradner JE, Kelliher MA.

Blood. 2014 Feb 13;123(7):1040-50. doi: 10.1182/blood-2013-08-522698. Epub 2014 Jan 6.

13.

NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells.

Dos Santos NR, Ghezzo MN, da Silva RC, Fernandes MT.

Cancers (Basel). 2010 Nov 5;2(4):1838-60. doi: 10.3390/cancers2041838.

14.

Lessons from next-generation sequencing analysis in hematological malignancies.

Braggio E, Egan JB, Fonseca R, Stewart AK.

Blood Cancer J. 2013 Jul 19;3:e127. doi: 10.1038/bcj.2013.26.

15.

The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.

Tosello V, Ferrando AA.

Ther Adv Hematol. 2013 Jun;4(3):199-210. doi: 10.1177/2040620712471368.

16.

Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.

Chu Q, Orr BA, Semenkow S, Bar EE, Eberhart CG.

Clin Cancer Res. 2013 Jun 15;19(12):3224-33. doi: 10.1158/1078-0432.CCR-12-2119. Epub 2013 Apr 29.

17.

Notch1 signaling is involved in regulating Foxp3 expression in T-ALL.

Luo X, Tan H, Zhou Y, Xiao T, Wang C, Li Y.

Cancer Cell Int. 2013 Apr 11;13(1):34. doi: 10.1186/1475-2867-13-34.

18.

Blockade of individual Notch ligands and receptors controls graft-versus-host disease.

Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT, Radojcic V, Friedman A, Gridley T, Shelton A, Reddy P, Samuelson LC, Yan M, Siebel CW, Maillard I.

J Clin Invest. 2013 Apr;123(4):1590-604.

19.

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.

Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, Perrimon N, Pear WS, Kung AL, Blacklow SC, Aster JC, Stegmaier K.

Cancer Cell. 2013 Mar 18;23(3):390-405. doi: 10.1016/j.ccr.2013.01.015. Epub 2013 Feb 21.

20.

MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Sionov RV.

ISRN Hematol. 2013;2013:348212. doi: 10.1155/2013/348212. Epub 2013 Jan 29.

Supplemental Content

Support Center